Life Sciences Companies Embrace 6 Hybrid Financing Tactics as High Rates Squeeze VC and IPO Funding
Updated
Updated · MedCity News · Jul 19
Life Sciences Companies Embrace 6 Hybrid Financing Tactics as High Rates Squeeze VC and IPO Funding
1 articles · Updated · MedCity News · Jul 19
Summary
Hybrid and crossover financing has moved from niche to essential in life sciences, with companies using royalties, structured debt and flexible capital stacks to keep raising money despite tight VC markets and slow IPO recovery.
High interest rates, regulatory volatility and reimbursement pressure are pushing investors and companies toward blended structures that can reduce dilution, spread risk and preserve cash while funding clinical, regulatory and commercialization milestones.
Those structures are also becoming a bridge to M&A as buyers move earlier in the development cycle, giving targets fresh capital and investors structured protections plus multiple paths to liquidity.
The report highlights 6 priorities for dealmakers, including building syndicates early, matching funding models to subsectors, treating hybrids as a core strategy and using secondary markets for earlier liquidity.
The broader shift suggests life sciences financing is being rewired around more flexible, measurement-driven deals that can support scientific progress until equity markets become more favorable.